Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
Clinical Lung Cancer|March 8, 2020
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective StudyTianle Shen, Xingxiang Pu, Liping Wang, et al.
Oncology Letters|March 17, 2018
Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancerXiaohui Chen, Yujie Deng, Yi Shi, et al.
Therapeutic Advances in Medical Oncology|May 30, 2024
Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastasesYue Hao, Manyi Xu, Xiaohong Zeng, et al.
Annals of Translational Medicine|December 24, 2015
Diagnosis value of CD117 and PDGFRA, alone or in combination DOG1, as biomarkers for gastrointestinal stromal tumorsChunwei Xu, Hongyan Han, Jingjing Wang, et al.
Aging|November 19, 2024
A differentially-methylated-region signature predicts the recurrence risk for patients with early stage lung adenocarcinomaHeng Li, Fuchao Luo, Xiaoran Sun, et al.
Iscience|January 5, 2024
Notch activation defines immune-suppressive subsets of ccRCCs with unfavorable benefits from immunotherapy over VEGFR/mTOR inhibitorsSujun Han, Yu Xu, Dong Chen, et al.
Science China. Life Sciences|September 14, 2024
Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trialsJinliang Wang, Wenyong Zhou, Yu Xu, et al.
Clinical and Experimental Medicine|October 31, 2025
Notch pathway defines an aggressive and immune-suppressive phenotype associated with checkpoint inhibitor resistance in pan-gastrointestinal adenocarcinomasYang Luo, Roushu Wang, Yu Xu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 15, 2020
The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patientsZhengbo Song, Tianchi Liu, Lei Shi, et al.
Frontiers in Oncology|December 15, 2022
A prognostic signature based on adenosine metabolism related genes for ovarian cancerWeifeng Liang, Chao Zhou, Jingshu Wang, et al.
Pageof 15